Comparison of Efficacy and Safety Between Dronedarone and Amiodarone Used During the Blind Period in Patients with Atrial Fibrillation After Catheter Ablation

References

• Lin JL, Wu TJ, Chen CP, et al. Observational study of dronedarone in Taiwanese patients with atrial fibrillation. J Formos Med Assoc. 2020;119(1 Pt 1):59–68. doi:10.1016/j.jfma.2019.03.009
   PubMed Web of Science ®Google Scholar
• Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1–e160. doi:10.1093/europace/eux274
   PubMed Web of Science ®Google Scholar
• Shah S, Barakat AF, Saliba WI, et al. Recurrent Atrial Fibrillation After Initial Long-Term Ablation Success: electrophysiological Findings and Outcomes of Repeat Ablation Procedures. Circ Arrhythm Electrophysiol. 2018;11(4):e005785. doi:10.1161/CIRCEP.117.005785
   PubMed Web of Science ®Google Scholar
• Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI, Murphy EJ, Goldschlager N. Practical Management Guide for Clinicians Who Treat Patients with Amiodarone. Am J Med. 2016;129(5):468–475. doi:10.1016/j.amjmed.2015.08.039
   PubMed Web of Science ®Google Scholar
• Vamos M, Hohnloser SH. Amiodarone and dronedarone: an update. Trends Cardiovasc Med. 2016;26(7):597–602. doi:10.1016/j.tcm.2016.03.014
   PubMed Web of Science ®Google Scholar
• Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24(16):1481–1487. doi:10.1016/S0195-668X(03)00321-X
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10):987–999. doi:10.1056/NEJMoa054686
   PubMed Web of Science ®Google Scholar
• Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156(3):527.e1–9. doi:10.1016/j.ahj.2008.06.010
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668–678. doi:10.1056/NEJMoa0803778
   PubMed Web of Science ®Google Scholar
• Felser A, Blum K, Lindinger PW, Bouitbir J, Krähenbühl S. Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone. Toxicol Sci. 2013;131(2):480–490. doi:10.1093/toxsci/kfs298
   PubMed Web of Science ®Google Scholar
• Zimetbaum PJ. Dronedarone for atrial fibrillation--an odyssey. N Engl J Med. 2009;360(18):1811–1813. doi:10.1056/NEJMp0902248
   PubMed Web of Science ®Google Scholar
• Page RL, Connolly SJ, Crijns HJ, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol. 2011;107(7):1019–1022. doi:10.1016/j.amjcard.2010.11.028
   PubMed Web of Science ®Google Scholar
• Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011;13(3):329–345. doi:10.1093/europace/euq450
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597–605. doi:10.1111/j.1540-8167.2010.01764.x
   PubMed Web of Science ®Google Scholar
• Buiatti A, Kaess B, Reents T, et al. Catheter Ablation for “Lone” Atrial Fibrillation: Efficacy and Predictors of Recurrence. J Cardiovasc Electrophysiol. 2016;27:536–541.
   PubMed Web of Science ®Google Scholar
• Grindal AW, Sparrow RT, McIntyre WF, Conen D, Healey JS, Wong JA. Alcohol Consumption and Atrial Arrhythmia Recurrence After Atrial Fibrillation Ablation: a Systematic Review and Meta-analysis. Can J Cardiol. 2023;39(3):266–273. doi:10.1016/j.cjca.2022.12.010
   PubMed Web of Science ®Google Scholar
• Brilliant J, Yadav R, Akhtar T, Calkins H, Trayanova N, Spragg D. Clinical and Structural Factors Affecting Ablation Outcomes in Atrial Fibrillation Patients - A Review. Curr Cardiol Rev. 2023;19(5):83–96. doi:10.2174/1573403X19666230331103153
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Nitta J, Kobori A, et al. Alcohol Consumption Reduction and Clinical Outcomes of Catheter Ablation for Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2021;14(6):e009770. doi:10.1161/CIRCEP.121.009770
   PubMed Web of Science ®Google Scholar
• Shang Y, Chen N, Wang Q, et al. Blood lipid levels and recurrence of atrial fibrillation after radiofrequency catheter ablation: a prospective study. J Interv Card Electrophysiol. 2020;57(2):221–231. doi:10.1007/s10840-019-00543-w
   PubMed Web of Science ®Google Scholar
• Li ZZ, Liu T, Huang Q, et al. Association Between Pre-Radiofrequency Catheter Ablation Serum Lipid Levels and Recurrence of Atrial Fibrillation in 412 Patients in Beijing, China: a Single-Center Study. Med Sci Monit. 2023;29:e938288. doi:10.12659/MSM.938288
   PubMed Web of Science ®Google Scholar
• Ding M, Wennberg A, Gigante B, Walldius G, Hammar N, Modig K. Lipid levels in midlife and risk of atrial fibrillation over 3 decades-Experience from the Swedish AMORIS cohort: a cohort study. PLoS Med. 2022;19:e1004044. doi:10.1371/journal.pmed.1004044
   PubMedGoogle Scholar
• Harrison SL, Lane DA, Banach M, et al. Lipid levels, atrial fibrillation and the impact of age: results from the LIPIDOGRAM2015 study. Atherosclerosis. 2020;312:16–22. doi:10.1016/j.atherosclerosis.2020.08.026
   PubMed Web of Science ®Google Scholar
• Yang S, Pudasaini R, Zhi H, Wang L. The Relationship between Blood Lipids and Risk of Atrial Fibrillation: univariable and Multivariable Mendelian Randomization Analysis. Nutrients. 2021;14(1):181. doi:10.3390/nu14010181
   PubMed Web of Science ®Google Scholar
• Li X, Gao L, Wang Z, et al. Lipid profile and incidence of atrial fibrillation: a prospective cohort study in China. Clin Cardiol. 2018;41(3):314–320. doi:10.1002/clc.22864
   PubMed Web of Science ®Google Scholar
• Pieragnoli P, Paoletti Perini A, Ricciardi G, et al. Recurrences in the Blanking Period and 12-Month Success Rate by Continuous Cardiac Monitoring After Cryoablation of Paroxysmal and Non-Paroxysmal Atrial Fibrillation. J Cardiovasc Electrophysiol. 2017;28(6):625–633. doi:10.1111/jce.13190
   PubMed Web of Science ®Google Scholar
• Mugnai G, de Asmundis C, Hünük B, et al. Second-generation cryoballoon ablation for paroxysmal atrial fibrillation: predictive role of atrial arrhythmias occurring in the blanking period on the incidence of late recurrences. Heart Rhythm. 2016;13(4):845–851. doi:10.1016/j.hrthm.2015.12.034
   PubMed Web of Science ®Google Scholar
• Choi JI, Pak HN, Park JS, et al. Clinical significance of early recurrences of atrial tachycardia after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2010;21(12):1331–1337. doi:10.1111/j.1540-8167.2010.01831.x
   PubMed Web of Science ®Google Scholar
• Willems S, Khairy P, Andrade JG, et al. Redefining the Blanking Period After Catheter Ablation for Paroxysmal Atrial Fibrillation: insights From the ADVICE (Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination) Trial. Circ Arrhythm Electrophysiol. 2016;9(8). doi:10.1161/CIRCEP.115.003909
   Web of Science ®Google Scholar
• Gottlieb LA, Dekker L, Coronel R. The Blinding Period Following Ablation Therapy for Atrial Fibrillation: proarrhythmic and Antiarrhythmic Pathophysiological Mechanisms. JACC Clin Electrophysiol. 2021;7(3):416–430. doi:10.1016/j.jacep.2021.01.011
   PubMedGoogle Scholar
• Vaishnav AS, Levine E, Coleman KM, et al. Early recurrence of atrial fibrillation after pulmonary vein isolation: a comparative analysis between cryogenic and contact force radiofrequency ablation. J Interv Card Electrophysiol. 2020;57(1):67–75. doi:10.1007/s10840-019-00639-3
   PubMed Web of Science ®Google Scholar
• Roux JF, Zado E, Callans DJ, et al. Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study). Circulation. 2009;120(12):1036–1040. doi:10.1161/CIRCULATIONAHA.108.839639
   PubMed Web of Science ®Google Scholar
• Kaitani K, Inoue K, Kobori A, et al. Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial. Eur Heart J. 2016;37(7):610–618. doi:10.1093/eurheartj/ehv501
   PubMed Web of Science ®Google Scholar
• Lodziński P, Kiliszek M, Koźluk E, et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiol J. 2014;21(4):384–391. doi:10.5603/CJ.a2013.0144
   PubMed Web of Science ®Google Scholar
• Piccini JP, Sinner MF, Greiner MA, et al. Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. Circulation. 2012;126(18):2200–2207. doi:10.1161/CIRCULATIONAHA.112.109330
   PubMed Web of Science ®Google Scholar
• Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9(9):CD005049. doi:10.1002/14651858.CD005049.pub5
   PubMedGoogle Scholar
• Opie LH, Schwartz PJ. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2012;366(12):1159.
   PubMedGoogle Scholar
• Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–2687. doi:10.1056/NEJMoa0800456
   PubMed Web of Science ®Google Scholar
• Guerra F, Hohnloser SH, Kowey PR, et al. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. Clin Cardiol. 2014;37(12):717–724. doi:10.1002/clc.22342
   PubMed Web of Science ®Google Scholar
• Prystowsky EN. Atrial fibrillation: dronedarone and amiodarone-The safety versus efficacy debate. Nat Rev Cardiol. 2010;7(1):5–6. doi:10.1038/nrcardio.2009.221
   PubMed Web of Science ®Google Scholar
• Gao S, Dai W, Zhang L, Juhaeri J, Wang Y, Caubel P. Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: dronedarone versus Amiodarone and Other Antiarrhythmics. J Atr Fibrillation. 2013;6(4):890. doi:10.4022/jafib.890
   PubMedGoogle Scholar
• Sr HD, Nandkeolyar S, Lan H, et al. Amiodarone: a Comprehensive Guide for Clinicians. Am J Cardiovasc Drugs. 2020;20(6):549–558. doi:10.1161/CIRCULATIONAHA.109.875252
   PubMed Web of Science ®Google Scholar
• Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121(9):676–683. doi:10.7326/0003-4819-121-9-199411010-00009
   PubMed Web of Science ®Google Scholar
• Grymonprez M, Carnoy L, Capiau A, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother;2023. pvad070. doi:10.1093/ehjcvp/pvad070
   PubMed Web of Science ®Google Scholar
• Shirolkar SC, Fiuzat M, Becker RC. Dronedarone and vitamin K antagonists: a review of drug-drug interactions. Am Heart J. 2010;160(4):577–582. doi:10.1016/j.ahj.2010.07.008
   PubMed Web of Science ®Google Scholar
• Friberg L. Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Int J Cardiol. 2018;264:85–90. doi:10.1016/j.ijcard.2018.02.055
   PubMed Web of Science ®Google Scholar
• Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331–342. doi:10.1007/s40256-013-0029-0
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg Bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120(13):1174–1180.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54(12):1089–1095. doi:10.1016/j.jacc.2009.04.085
   PubMed Web of Science ®Google Scholar